[
  {
    "ts": null,
    "headline": "Retirement Ready: 3 Dividend Stocks to Set and Forget",
    "summary": "These are three rock-solid dividend stocks you can buy now and confidently forget, knowing they’ll keep working for you year after year.",
    "url": "https://finnhub.io/api/news?id=dd175c50c7605b62eab80d3890d2fae4b2289978a1326a1a61a7d4c967c00ccc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752622202,
      "headline": "Retirement Ready: 3 Dividend Stocks to Set and Forget",
      "id": 135959172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These are three rock-solid dividend stocks you can buy now and confidently forget, knowing they’ll keep working for you year after year.",
      "url": "https://finnhub.io/api/news?id=dd175c50c7605b62eab80d3890d2fae4b2289978a1326a1a61a7d4c967c00ccc"
    }
  },
  {
    "ts": null,
    "headline": "Trump Says Drug Tariffs Probable by Aug. 1, Downplays More Deals",
    "summary": "(Bloomberg) -- President Donald Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month and that levies on semiconductors could come soon as well, suggesting that those import taxes could hit alongside broad “reciprocal” rates set for implementation on Aug. 1.Most Read from BloombergThe Dutch Intersection Is Coming to Save Your LifeAdvocates Fear US Agents Are Using ‘Wellness Checks’ on Children as a Prelude to ArrestsLA Homelessness Drops for Second YearMan",
    "url": "https://finnhub.io/api/news?id=2e64ed0720018a95139fe7b4de57bba326a5f5f91c3662abe605a43aaea27033",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752621803,
      "headline": "Trump Says Drug Tariffs Probable by Aug. 1, Downplays More Deals",
      "id": 135964684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- President Donald Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month and that levies on semiconductors could come soon as well, suggesting that those import taxes could hit alongside broad “reciprocal” rates set for implementation on Aug. 1.Most Read from BloombergThe Dutch Intersection Is Coming to Save Your LifeAdvocates Fear US Agents Are Using ‘Wellness Checks’ on Children as a Prelude to ArrestsLA Homelessness Drops for Second YearMan",
      "url": "https://finnhub.io/api/news?id=2e64ed0720018a95139fe7b4de57bba326a5f5f91c3662abe605a43aaea27033"
    }
  },
  {
    "ts": null,
    "headline": "XPH: Healthcare Dashboard For July",
    "summary": "XPH ETF offers equal-weighted exposure to pharmaceutical companies, with lackluster results for a decade. Click here to find out why XPH stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=f06d8fa42a12451bc189fb589853168778c65a1452470f7473adbf64804e67f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752599588,
      "headline": "XPH: Healthcare Dashboard For July",
      "id": 135956660,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1557045133/image_1557045133.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "XPH ETF offers equal-weighted exposure to pharmaceutical companies, with lackluster results for a decade. Click here to find out why XPH stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=f06d8fa42a12451bc189fb589853168778c65a1452470f7473adbf64804e67f9"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=0574ae0413e4e1281bb110c936c6c2e96d51c046c4ab5c4b5f0c233e8a9062b3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752597360,
      "headline": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
      "id": 135977197,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=0574ae0413e4e1281bb110c936c6c2e96d51c046c4ab5c4b5f0c233e8a9062b3"
    }
  },
  {
    "ts": null,
    "headline": "Morningstar Reduces Moat Rating For Pfizer (PFE) To Narrow",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the Best Large Cap Value Stocks to Invest In. Morningstar reduced its moat rating for the company to narrow due to the portfolio setbacks as well as policy risk. That being said, the firm also added that Pfizer Inc. (NYSE:PFE)’s foundation is strong on the basis of steady cash flows coming […]",
    "url": "https://finnhub.io/api/news?id=e5d175f5c2b65cd615f53aa7c42a56d356eb141d4adf2bff53443d4d8625b4a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752595239,
      "headline": "Morningstar Reduces Moat Rating For Pfizer (PFE) To Narrow",
      "id": 135965499,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the Best Large Cap Value Stocks to Invest In. Morningstar reduced its moat rating for the company to narrow due to the portfolio setbacks as well as policy risk. That being said, the firm also added that Pfizer Inc. (NYSE:PFE)’s foundation is strong on the basis of steady cash flows coming […]",
      "url": "https://finnhub.io/api/news?id=e5d175f5c2b65cd615f53aa7c42a56d356eb141d4adf2bff53443d4d8625b4a7"
    }
  },
  {
    "ts": null,
    "headline": "ViiV’s HIV shot preferred, as activists spotlight funding crisis at IAS 2025",
    "summary": "Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.",
    "url": "https://finnhub.io/api/news?id=828cfe6f6df0c6de0bb1bbf627f3de0f15dd0be365fe0c2674227501a9d112bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752589456,
      "headline": "ViiV’s HIV shot preferred, as activists spotlight funding crisis at IAS 2025",
      "id": 135962356,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.",
      "url": "https://finnhub.io/api/news?id=828cfe6f6df0c6de0bb1bbf627f3de0f15dd0be365fe0c2674227501a9d112bb"
    }
  },
  {
    "ts": null,
    "headline": "How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?",
    "summary": "PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.",
    "url": "https://finnhub.io/api/news?id=0314a594a3ab2e3279ed46e07017950680c9defc69730d04f33caa55d120555f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752584040,
      "headline": "How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?",
      "id": 135965230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.",
      "url": "https://finnhub.io/api/news?id=0314a594a3ab2e3279ed46e07017950680c9defc69730d04f33caa55d120555f"
    }
  },
  {
    "ts": null,
    "headline": "OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company",
    "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. .",
    "url": "https://finnhub.io/api/news?id=846f69128d1bf1433e1c3ba2bea25533c9214e9e6db289110eca4c986d491f0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752579000,
      "headline": "OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company",
      "id": 135941909,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. .",
      "url": "https://finnhub.io/api/news?id=846f69128d1bf1433e1c3ba2bea25533c9214e9e6db289110eca4c986d491f0d"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Value Equity Fund Q2 2025 Commentary",
    "summary": "Parnassus Value Equity Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=8da32aa99f91d77430a6333e00c9076e612b9dbc7e69491bd5ddc74be3c14dc2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752569820,
      "headline": "Parnassus Value Equity Fund Q2 2025 Commentary",
      "id": 135943720,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8da32aa99f91d77430a6333e00c9076e612b9dbc7e69491bd5ddc74be3c14dc2"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Great Starting Yield For This Wealth Compounder",
    "summary": "Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment.",
    "url": "https://finnhub.io/api/news?id=43424ea61b871b3eb0aef6fd5619c80550422fec595c0c4b232b73874992cca5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752566400,
      "headline": "Amgen: Great Starting Yield For This Wealth Compounder",
      "id": 135942663,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment.",
      "url": "https://finnhub.io/api/news?id=43424ea61b871b3eb0aef6fd5619c80550422fec595c0c4b232b73874992cca5"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Value Select ETF Q2 2025 Commentary",
    "summary": "Parnassus Value Select ETF returned 6.38% (net of fees) for the quarter, outperforming the Russell 1000 Value Indexâs 3.79%. Read more here.",
    "url": "https://finnhub.io/api/news?id=887fa1fb52e2f86d27202dd5cd4ecc464bf49989b2ee52d157dc6864ed4a4a14",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752564480,
      "headline": "Parnassus Value Select ETF Q2 2025 Commentary",
      "id": 135941970,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220503680/image_2220503680.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Parnassus Value Select ETF returned 6.38% (net of fees) for the quarter, outperforming the Russell 1000 Value Indexâs 3.79%. Read more here.",
      "url": "https://finnhub.io/api/news?id=887fa1fb52e2f86d27202dd5cd4ecc464bf49989b2ee52d157dc6864ed4a4a14"
    }
  },
  {
    "ts": null,
    "headline": "Oxford Biodynamics soars after test method is used in Pfizer trial",
    "summary": "Oxford Biodynamics PLC on Tuesday said its biomarkers were shown to be effective indicators of cancer in trials conducted by Pfizer Inc.The Oxford, England-based biotechnology company develops...",
    "url": "https://finnhub.io/api/news?id=13ed6369ea913c918c923fefd836ff8229bd643267e93a0b2d535c4334cc02b1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752562392,
      "headline": "Oxford Biodynamics soars after test method is used in Pfizer trial",
      "id": 135941170,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Oxford Biodynamics PLC on Tuesday said its biomarkers were shown to be effective indicators of cancer in trials conducted by Pfizer Inc.The Oxford, England-based biotechnology company develops...",
      "url": "https://finnhub.io/api/news?id=13ed6369ea913c918c923fefd836ff8229bd643267e93a0b2d535c4334cc02b1"
    }
  }
]